openPR Logo
Press release

Multiple Sclerosis Therapeutics Market - Global Trends, and Forecast till 2025

02-17-2018 09:09 AM CET | Health & Medicine

Press release from: Pharmaceutical Report By CMI

Multiple Sclerosis Therapeutics Market - Global Trends,

Multiple Sclerosis Therapeutics Market – Offering Long-term Disease Management

Multiple sclerosis (MS) is a disabling autoimmune disease affecting the brain and the spinal cord, eventually causing nerve deterioration or permanent damage. The types of MS include relapsing-remitting MS (RRMS), primary progressive MS (PPMS) and secondary progressive MS (SPMS). RPMS is the most common type characterized by defined attacks with increasing neurological symptoms, PPMS is the rare form characterized by gradual progression of disease, whereas SPMS is commonly identified in people living with relapsed-remitting MS. The most common symptoms of the disease include partial or complete vision loss, prolonged vision loss, lack of coordination and slurred speech.

A combination of genetic and environmental factors is responsible for the occurrence of the condition. According to a study by International Progressive Alliance, 2013, MS is two to three times more common in women than in men, suggesting that hormones play a significant role in determining susceptibility to the disease.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1310

The global multiple sclerosis therapeutics market was valued at US$ 19.6 billion in 2016 and is expected to witness a robust CAGR of 2.5% over the forecast period (2017 - 2025).

Increasing prevalence of multiple sclerosis to augment market growth

Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years. According to the Multiple Sclerosis Foundation, 2017, this autoimmune condition affects 2.5 million people with the global incidence of around 7 cases per 100,000 people per year. The study also states that prevalence rates varies between ethnic and geographical latitudes, ranging from 50 to 120 people per 100,000 population. North America dominates the multiple sclerosis therapeutics market owing to the high prevalence of the condition and the rising economic burden of the disease leading to the adoption of novel therapeutics. According to the Multiple Sclerosis Foundation, 2015, an estimated 400,000 people live with the disease in U.S., and about 200 new cases are diagnosed every week. According to a survey by Healthline Media, 2015, multiple sclerosis ranks second after congestive heart failure with direct and indirect health care costs ranging from US$ 8,528 to US$ 54,244 per patient per year. Higher therapy cost is restraining the growth of the multiple sclerosis therapeutics market.

Intensive R&D programs undertaken by organizations to accelerate the market growth

Various organizations such as National Institute of Neurological Disorders and Stroke, National MS Society, Parkinson’s Action Network are undertaking extensive efforts to create novel therapies for MS, contributing to be a vital factor driving the growth of global multiple sclerosis therapeutics market. For instance, the scientists at Multiple Sclerosis International Federation are undertaking research to understand, manage and treat the disease and are currently undertaking clinical trials to investigate the potential of stem cell therapies including mesenchymal stem cell (MSCs), hematopoietic stem cells (HSCs) and neural stem cells (NSCs). Also, in 2013, the Progressive MS Alliance was established to specifically research and develop more treatment options for people with the progressive forms of MS which currently has a total of 20 projects with researchers based in nine countries. Additionally, in 2015, the MS Society of Canada and the Canadian Institute of Health Research funded a new research to the University of Alberta to examine novel therapeutic strategy to reduce inflammation in the brain, a key factor contributing to the muscle disability associated with multiple sclerosis.

Click here to know more about this publish report: https://www.coherentmarketinsights.com/market-insight/multiple-sclerosis-therapeutics-market-1310

The major players operating in the global multiple sclerosis therapeutics market include Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Bayer AG, Pfizer, Inc., Biogen Idec, Merck & Co., Inc., and AbbVie, Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit our news Website: http://www.coherentchronicle.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Multiple Sclerosis Therapeutics Market - Global Trends, and Forecast till 2025 here

News-ID: 947072 • Views: 502

More Releases from Pharmaceutical Report By CMI

Rising prevalence of diabetes is a major factor driving growth of the diabetic f …
Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the
Glucagon-Like Peptide-1 (Glp-1) Analogs Market Global Industry Insights, Trends, …
Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic
Multiple Sclerosis Therapeutics Market to Surpass US$ 24.4 Billion by 2025
Increasing prevalence of multiple sclerosis to augment market growth Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years. According to the Multiple Sclerosis Foundation, 2017, this autoimmune condition affects 2.5 million people with the global incidence of around 7 cases per 100,000 people per year. The study also states that prevalence rates varies between ethnic and geographical latitudes, ranging from 50 to
Diabetic Foot Ulcers Treatment Market to Surpass US$ 9.49 Billion Threshold by 2 …
Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the

All 5 Releases


More Releases for Multiple

Global Multiple Sclerosis Market Size, Global Multiple Sclerosis Market Share, G …
The Global Multiple Sclerosis Market Size is majorly driven by the factors such as rising number of consolidations between the market players for exploring the untapped market opportunity across the world. Request for Sample of This Research Report @ https://bit.ly/2Nh6b4d Top Key Player:- Hoffmann-La Roche Ltd. Bayer Healthcare AG Teva Pharmaceuticals GlaxoSmithKline AbbVie Inc. Sonafi Pasteur Pfizer Inc. Merck & Company Novartis AG AB Science Opexa Multiple Sclerosis (MS) is a disease in which the insulating covers of nerves and spinal cord are
Thermoseal Group Multiple Award Winners
For the second year in a row, Thermoseal Group is the winner of the coveted Glass and Glazing Industry’s G-Award for ‘Component Supplier of the Year’ as announced at the prestigious Gala Dinner held at the Hilton on Park Lane Hotel in London on Friday 18 November 2016. This was a great day for Thermoseal Group who were also announced winners at two other awards events held that day
Reduce Headaches Updating Multiple Spreadsheets
Melbourne, Australia – DataMystic announces ExcelPipe 7.5, its enhanced mass-replacement utility for Microsoft Excel. Do you make the same change to a group of Excel Spreadsheets, over and over again? End of calendar year? End of financial year? And you know how tedious that is? ExcelPipe is a time-saving search and replace tool designed to work hand-in-hand with Microsoft Excel to change thousands of Spreadsheets automatically. It saves weeks of manual labor
Reduce Headaches Updating Multiple Documents
Reduce Headaches Updating Multiple Documents Melbourne, Australia – DataMystic announces WordPipe 9.4, its enhanced mass-replacement utility for Microsoft Word. Do you make the same change to a group of Word documents, over and over again? And you know how tedious that is? WordPipe is a time-saving search and replace tool designed to work hand-in-hand with Microsoft Word to change thousands of documents automatically. It saves weeks of manual labor when links need changing,
Formulating Cosmetics For Multiple Markets
With all the regulatory information and expertise available, it’s worth considering the destination markets where you want to sell a product as the basis for the formulation you use. For example, when formulating products destined for the US market, you should consider the demands of federal and state legislation – in as many states as you want to sell into. If California is one of them, you need to know if
Multiple measurements with only one pressure gauge
Multi-station gauge isolator valves allow control of up to 6 measuring points in the hydraulic system Multi-station gauge isolator valves of type SWS-M from Stauff allow the measuring of the operating pressure in hydraulic systems on up to six different measuring points in the system with only one display device. This is generally an analogue or digital pressure gauge. The measuring point to be monitored is selected by turning the knob